Absci Corp

Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. It partners with pharma and biotech innovators to create the next generation of protein-based drugs. The company was founded by Sean McClain in 2011 and is headquartered in Vancouver, WA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Absci Corp reports solid Q1 performance, highlights platform efficiency

Absci Corp's Q1 2024 performance reflects a focus on innovation with significant R&D investment and revenue generation, supported by a strong cash position
The company's hybrid business model and progress on internal pipeline programs showcase efficiency and commitment to advancing multiple therapeutic candidates

Absci Corp reports strong Q2 earnings, expands oncology programs

Absci Corp's Q2 2024 earnings call highlighted strong financials, progress in pipeline programs, and strategic collaborations with MSK and other partners.
The company's focus on immunology and oncology, supported by AI capabilities and a healthy cash position, positions Absci for future growth and innovation.
While facing challenges in managing R&D expenses and advancing validation studies, Absci has opportunities to drive innovation and establish a leading position in the market.
Overall, Absci's performance in Q2 2024 reflects a company poised for growth, with a solid foundation to drive research, development, and strategic partnerships.

Absci Corp reports solid Q3 earnings, eyes strategic partnerships for growth

Absci Corp's Q3 2024 performance reflects steady revenue growth, prudent cost management, and strong cash reserves.
The company's strategic collaborations and upcoming R&D Day signal a focus on innovation, partnerships, and future growth.
While challenges in managing expenses persist, Absci Corp's opportunities lie in expanding partnerships, showcasing technology, and driving market interest.
Overall, Absci Corp's emphasis on execution, upcoming catalysts, and financial discipline positions it for continued success in the biotech sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Seven program deal with stealth-mode ADC company to leverage Absci's Bionic Protein™ technology Seven program deal with stealth-mode ADC company to leverage Absci's Bionic Protein™ technology

Absci Enters Multi-Program Collaboration with Emerging Biotech Partner

VANCOUVER, Wash., May 11, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today reported financial and operating results for the quarter ended March 31, 2022.

Absci Reports First Quarter 2022 Financial and Operating Results

Absci, the Vancouver, Wash.-based biotech that provides drug and drug target discovery services to other companies, has opened a lab in New York City. The company announced the opening of the Absci AI Research Lab in Manhattan's Plaza District on Wednesday, saying that the space with panoramic views of Central Park is “designed to energize and inspire innovation.” The AAIR Lab will build on the company's recent breakthroughs in machine learning for in silico antibody lead optimization, as well as its announcement of its collaboration with NVIDIA. It will also advance Absci's therapeutic protein design. “We're eager to tap into the deep… Read More

Vancouver, Wash.-based biotech Absci opens new AI Research Lab in New York City

Financial Highlights of the year ended December 31, 2021: Revenue amounted to RMB2,104.1 million, representing a year-on-year (YoY) increase of 201.9% Gross profit amounted to RMB651.0 million, representing a YoY increase of 113.5% Adjusted Non-IFRS net profit amounted to RMB352.5 million Adjusted earnings per share amounted to HK$0.21 HONGKONG, March 28, 2022 /PRNewswire/ -- On March 28, 2022, Viva Biotech Holdings (1873.HK) announced that during the year ended December 31, 2021 (the "Reporting Period"), the revenue of the Group increased significantly to RMB2,104.1 million from RMB697.0 million for the corresponding period last year, representing a YoY increase of approximately 201.9%, gross profit increased substantially from RMB304.9 million for the corresponding period last year to RMB651.0 million, representing a YoY increase of 113.5%. The adjusted net profit of the Group increased from RMB252.3 million for the corresponding period last year to RMB352.5 million, representing a YoY increase of 39.7%.

Viva Biotech Announced 2021 Annual Results: Revenue Increased by 201.9% YoY, CRO Business Revenue Maintained Rapid Growth with an Increase of 68.7%

Absci Corp (NASDAQ: ABSI) shares are trading lower by 9.2% at $6.79 after the company reported fourth-quarter earnings results. Absci reported quarterly losses of 28 cents per share.

Here's Why Absci Corp Shares Are Falling

VANCOUVER, Wash., March 22, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today reported financial and operating results for the quarter and full year ended December 31, 2021.

Absci Reports Full Year 2021 Financial and Operating Results

Absci to present in-silico drug discovery technology at NVIDIA GTC

Absci Develops Groundbreaking Machine Learning Models for In-Silico Antibody Design, Powered by NVIDIA

Dr. Busch brings deep operational expertise in drug discovery to Absci's Board Dr. Busch brings deep operational expertise in drug discovery to Absci's Board

Absci Appoints Dr. Andreas Busch to Board of Directors

VANCOUVER, Wash., March 16, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a drug and target discovery company harnessing deep learning, AI and synthetic biology to expand the therapeutic potential of proteins, today announced that Absci Lead AI Scientist Joshua Meier will be presenting at NVIDIA GTC .

Absci to Present at Global AI Conference NVIDIA GTC

Absci (ABSI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Absci (ABSI) This Earnings Season?

VANCOUVER, Wash., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the company will be participating virtually in the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference.

Absci to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Merck

Absci (ABSI) signs a deal with Merck for using its AI-powered drug creation platform to produce enzymes for Merck's biomanufacturing applications with an option for the development of three novel drugs.

Absci (ABSI) Inks Research Agreement With Merck, Stock Up

Absci Corporation (NASDAQ: ABSI) went up 50% after it announced that it had executed a research and collaboration agreement with Merck, commonly referred to as MSD outside Canada and the US. The company came to this agreement via its AI-powered Integrated Drug Creation Platform.

Absci Corp up 50% after announcing research collaboration with Merck

Absci (ABSI) stock is flying higher on Friday after announcing a major research collaboration agreement with Merck (MRK). The post ABSI Stock: 7 Things for Investors to Know About the Merck Deal That Has Absci Shares Flying Today appeared first on InvestorPlace.

ABSI Stock: 7 Things for Investors to Know About the Merck Deal That Has Absci Shares Flying Today

Absci Corp (NASDAQ: ABSI) is trading higher Friday after the company announced a research collaboration with Merck & Co Inc (NYSE: MRK). The collaboration will utilize Absci's AI-powered Integrated Drug Creation Platform.

Why Absci Shares Are Soaring Today

Shares of Absci Corp. ABSI, -12.78% skyrocketed 59.1% on heavy volume in premarket trading Friday, after the biotechnology company said it could be eligible to receive up to $610 million in upfront fees and milestone payments from Merck & Co. Inc. MRK, -0.06% as part of a research collaboration agreement. Trading volume ballooned to 9.7 million shares, compared with the full-day average of about 324,800 shares, to make the stock the biggest gainer and most actively traded ahead of the open.

Absci stock rockets after collaboration with Merck could lead to more than $600 million in payments

The stock price of Absci Corp (NASDAQ: ABSI) increased by over 30% pre-market today. This is why it happened.

Absci Stock (ABSI): Why The Price Surged Today

Collaboration to leverage Absci's Deep Learning-Enabled Drug Creation™ and Bionic Protein™ technologies Collaboration to leverage Absci's Deep Learning-Enabled Drug Creation™ and Bionic Protein™ technologies

Absci Announces Research Collaboration with Merck

VANCOUVER, Wash., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the company will be participating virtually in the upcoming 40th Annual J.P. Morgan Healthcare Conference.

Absci to Participate in the 40th Annual J.P. Morgan Healthcare Conference

VANCOUVER, Washington, Dec. 30, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the company will be participating in the H.C. Wainwright BIOCONNECT Virtual Conference.

Absci to Participate in the H.C. Wainwright BIOCONNECT Virtual Conference

New York, New York--(Newsfile Corp. - November 28, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Absci Corporation (Absci" or the "Company") (NASDAQ: ABSI). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Absci and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Absci Corporation - ABSI

Absci Corporation (ABSI) CEO Sean McClain on Q3 2021 Results - Earnings Call Transcript

VANCOUVER, Wash., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today reported financial and operating results for the quarter ended September 30, 2021.

Absci Reports Third Quarter 2021 Financial and Operating Results

Absci cut the ribbon on its new headquarters in Vancouver, Wash.

Biotech company Absci, which recently went public, cuts ribbon on new HQ in Vancouver, Wash.

Vancouver, Washington headquarters expands company's ability to accelerate discovery and development of next generation biologic drugs Vancouver, Washington headquarters expands company's ability to accelerate discovery and development of next generation biologic drugs

News for Absci Corp Stock (ABSI)